Cinacalcet HCl reduces parathyroid hormone (PTH) in patients with stage 3 and 4 chronic kidney disease (CKD)

被引：0
|
作者：
Chonchol, M
Kopyt, N
Herman, J
Charytan, C
Pischettes, V
Olson, KA
Turner, SA
Coburn, JW
机构：
[1] Univ Colorado, Hlth Sci Ctr, Denver, CO USA
[2] NE Clin Res, Allentown, PA USA
[3] Palmetto Int Med, Columbia, SC USA
[4] NY Hosp Med Ctr Queens, Flushing, NY USA
[5] Hop Maison Neuve Rosemont, Montreal, PQ, Canada
[6] Amgen Inc, Thousand Oaks, CA USA
[7] VA Greater LA Hlth Care Serv, Los Angeles, CA USA
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 2004年 / 43卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
18
引用
收藏
页码：A19 / A19
页数：1
相关论文
共 50 条
  • [1] Calcium, phosphate and parathyroid hormone (PTH) abnormalities in patients with chronic kidney disease stage 3 (CKD 3)
    Richards, Nick
    Eames, Mick
    Mansell, Martin
    Lewis, Robert
    O'Donoghue, Donal
    Harris, Kevin
    Marcelli, Daniele
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 130 - 130
  • [2] Cinacalcet HCl Treatment in Patients with Chronic Kidney Disease Stage 3-4
    Tominaga, Yoshihiro
    [J]. CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1465 - 1466
  • [3] Monitoring of calcium, phosphorus, and parathyroid hormone in patients with chronic kidney disease (CKD).
    Smith, RB
    Coley, KC
    Saul, MI
    ElZein, H
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 623A - 623A
  • [4] Clinical outcomes of patients with stage 4 chronic kidney disease (CKD)
    Conway, B.
    Whitworth, C.
    Harty, J.
    [J]. SCOTTISH MEDICAL JOURNAL, 2006, 51 (04) : 47 - 47
  • [5] Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease
    S. Geng
    Z. Kuang
    P.L. Peissig
    D. Page
    L. Maursetter
    K.E. Hansen
    [J]. Osteoporosis International, 2019, 30 : 2019 - 2025
  • [6] Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease
    Geng, S.
    Kuang, Z.
    Peissig, P. L.
    Page, D.
    Maursetter, L.
    Hansen, K. E.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2019, 30 (10) : 2019 - 2025
  • [7] Cinacalcet HCl: A novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease
    Quarles, LD
    [J]. KIDNEY INTERNATIONAL, 2005, 68 : S24 - S28
  • [8] Parathyroid hormone measurement in chronic kidney disease stage 5
    Adams, Heather
    Osypiw, Jacqui
    Barker, Lindsey
    Naik, Ramesh
    Vaux, Emma
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 261 - 261
  • [9] Cinacalcet HCl is an effective treatment for secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) not yet receiving dialysis.
    Coburn, JW
    Charytan, C
    Chonchol, M
    Herman, J
    Lien, YH
    Liu, W
    Klassen, P
    Yahaghi, AS
    Pichette, V
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 460A - 460A
  • [10] The pharmacokinetics (PK) of cinacalcet HCl are comparable in patients with chronic kidney disease (CKD) receiving hemodialysis (HD) or chronic ambulatory peritoneal dialysis (CAPD).
    Padhi, D
    Harris, R
    Salfi, M
    Yates, W
    Henday, L
    Hansen, J
    Sullivan, JT
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 461A - 461A
12345